SARAH ROOP APRN-FNP
Prescription History 1649782830
Nurse Practitioner - Family in Portland, ME


Quality Rating: 98.06 out of 100 score

NPI Status: Active since October 29, 2017

Contact Information

1250 FOREST AVE STE 301
PORTLAND, ME
ZIP 04103
Phone: (207) 797-5753

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SARAH ROOP APRN-FNP, an active Family specialist practicing in Portland, ME. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 76 documented patient claims. Among these therapy options, the most frequently utilized medication is Famotidine, which accounts for 39 claims alone.

Medication Index

No matching medications currently found on file.

Famotidine

Generic Formulation: FamotidineSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 39
30-Day Fills 73.0
Days Supply 2,190
ME State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.5
Peer Average Days Supply182
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $416.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.69

State Avg Cost Per Claim

$42.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Therapeutic Applications

Famotidine is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. This medication is also used to treat certain stomach and throat (esophagus) problems (such as erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as cough that doesn't go away, stomach pain, heartburn, and difficulty swallowing. Famotidine belongs to a class of drugs known as H2 blockers. This medication is also available without a prescription. It is used to prevent and treat heartburn and other symptoms caused by too much acid in the stomach (acid indigestion). If you are taking this medication for self-treatment, it is important to read the manufacturer's package instructions carefully so you know when to consult your doctor or pharmacist.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 21
30-Day Fills 49.6
Days Supply 1,485
ME State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills37.0
Peer Average Days Supply1,000
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $504.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.03

State Avg Cost Per Claim

$45.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 36.0
Days Supply 1,080
ME State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills83.4
Peer Average Days Supply2,481
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.5% less volume than the regional standard for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $444.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.80

State Avg Cost Per Claim

$30.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SARAH ROOP APRN-FNP provides transparency into local medical care patterns within Portland, ME.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.